JP2004533421A5 - - Google Patents

Download PDF

Info

Publication number
JP2004533421A5
JP2004533421A5 JP2002574998A JP2002574998A JP2004533421A5 JP 2004533421 A5 JP2004533421 A5 JP 2004533421A5 JP 2002574998 A JP2002574998 A JP 2002574998A JP 2002574998 A JP2002574998 A JP 2002574998A JP 2004533421 A5 JP2004533421 A5 JP 2004533421A5
Authority
JP
Japan
Prior art keywords
monolipopeptide
peptide
composition according
amino acids
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002574998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2002/002188 external-priority patent/WO2002076485A2/en
Publication of JP2004533421A publication Critical patent/JP2004533421A/ja
Publication of JP2004533421A5 publication Critical patent/JP2004533421A5/ja
Withdrawn legal-status Critical Current

Links

JP2002574998A 2001-03-27 2002-03-27 T1免疫応答とt2免疫応答との間で調節するためのワクチン Withdrawn JP2004533421A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27869801P 2001-03-27 2001-03-27
PCT/IB2002/002188 WO2002076485A2 (en) 2001-03-27 2002-03-27 Vaccine for modulating between t1 and t2 immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010255171A Division JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Publications (2)

Publication Number Publication Date
JP2004533421A JP2004533421A (ja) 2004-11-04
JP2004533421A5 true JP2004533421A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=23065998

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002574998A Withdrawn JP2004533421A (ja) 2001-03-27 2002-03-27 T1免疫応答とt2免疫応答との間で調節するためのワクチン
JP2010255171A Expired - Fee Related JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010255171A Expired - Fee Related JP5519477B2 (ja) 2001-03-27 2010-11-15 T1免疫応答とt2免疫応答との間で調節するためのワクチン

Country Status (9)

Country Link
US (3) US8198400B2 (cg-RX-API-DMAC7.html)
EP (1) EP1377275B1 (cg-RX-API-DMAC7.html)
JP (2) JP2004533421A (cg-RX-API-DMAC7.html)
AT (1) ATE343375T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002309141B2 (cg-RX-API-DMAC7.html)
CA (1) CA2441809C (cg-RX-API-DMAC7.html)
DE (1) DE60215627T2 (cg-RX-API-DMAC7.html)
ES (1) ES2424131T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002076485A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
ES2375992T3 (es) * 2002-04-15 2012-03-08 Oncothyreon Inc. Glucolipopéptidos sintéticos como vacunas.
CA2542327C (en) * 2003-10-14 2014-08-12 Biomira, Inc. Combination therapy for cancer
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
DK1896051T3 (en) * 2005-06-28 2015-01-05 Oncothyreon Inc PROCESS FOR THE TREATMENT OF PATIENTS WITH A mucinous glycoprotein (MUC1) vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
US8703180B1 (en) * 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
BRPI1009892A2 (pt) * 2009-03-24 2016-03-15 Transgène S A método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
BR112013021779A2 (pt) 2011-02-24 2017-09-19 Oncothyreon Inc vacina de glicolipopeptídeo baseada em muc1 com adjuvante.
CN106102771B (zh) 2014-01-07 2021-06-29 巴比塔·阿格拉沃尔 免疫调节组合物及其使用方法
US11065283B2 (en) 2015-08-25 2021-07-20 Babita Agrawal Immunomodulatory compositions and methods of use thereof
CN110418648B (zh) * 2017-02-22 2023-09-08 丁恩雨 一种编码人GM-CSF与多串连表位融合的mRNA癌症疫苗

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0203676B1 (en) 1985-04-19 1992-01-29 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic t cell response protective against a virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AU2247095A (en) 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
WO1996040236A1 (en) * 1995-06-07 1996-12-19 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecules and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1997034921A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
WO1997038010A2 (en) * 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
JP4480800B2 (ja) * 1997-05-08 2010-06-16 オンコシリオン・インコーポレイテッド 活性化t細胞および抗原パルス標識した抗原提示細胞を生成する方法
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) * 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
WO2001012217A1 (en) 1999-08-18 2001-02-22 Altarex Corp. Therapeutic antibody against muc-1 antigen and methods for their use
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
DK1210430T3 (da) 1999-09-08 2006-11-20 Transgene Sa MUC-1-afledte peptider
EP1232168B1 (en) 1999-11-15 2011-08-03 Oncothyreon Inc. Synthetic lipid-a analogs and uses thereof
CA2404327A1 (en) * 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
US20020160039A1 (en) 2000-12-01 2002-10-31 Biomira U.S.A., Inc. Preparation of large liposomes by infusion into peg
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
ES2375992T3 (es) 2002-04-15 2012-03-08 Oncothyreon Inc. Glucolipopéptidos sintéticos como vacunas.
JP5014573B2 (ja) 2002-05-09 2012-08-29 オンコサイレオン インコーポレーテッド 脂質aおよび他の炭水化物リガンド類似体
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
DK1896051T3 (en) 2005-06-28 2015-01-05 Oncothyreon Inc PROCESS FOR THE TREATMENT OF PATIENTS WITH A mucinous glycoprotein (MUC1) vaccine

Similar Documents

Publication Publication Date Title
JP2004533421A5 (cg-RX-API-DMAC7.html)
JP2828391B2 (ja) オリゴ糖を表面に有するリポソーム
Frezard Liposomes: from biophysics to the design of peptide vaccines
Arunagirinathan et al. Self-assembled surfactant nano-structures important in drug delivery: a review
AU2002311616B2 (en) A method for preparation of vesicles loaded with biological material and different uses thereof
RU2311911C2 (ru) Способ усиления иммунного ответа при вакцинации нуклеиновой кислотой
AU2007264205B2 (en) Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
JP5519477B2 (ja) T1免疫応答とt2免疫応答との間で調節するためのワクチン
US20020160039A1 (en) Preparation of large liposomes by infusion into peg
JPWO2021183563A5 (cg-RX-API-DMAC7.html)
US5576017A (en) Heterovesicular liposomes
JP2015166351A (ja) インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
AU2002219998A1 (en) Preparation of large liposomes by infusion into PEG
AU2002311616A1 (en) A method for preparation of vesicles loaded with biological material and different uses thereof
US9757428B2 (en) Designed peptides for tight junction barrier modulation
JPH05503521A (ja) 指状突起―融合リポソームおよびゲル
US20050058697A1 (en) Cell penetrating therapeutic agents
AU2002309141A1 (en) Vaccine for modulating between T1 and T2 immune responses
Bally et al. Novel procedures for generating and loading liposomal systems
KR20170016315A (ko) 알루미늄 염-흡착 백신의 면역자극 효력의 증진 방법
CA1330199C (en) Spontaneous vesiculation of multilamellar liposomes
CA2802443A1 (en) Vaccine compositions based on sticholysin encapsulated in liposomes
JPWO2023069498A5 (cg-RX-API-DMAC7.html)
WO2016103273A1 (en) A dna vaccine formulation in cationic liposome vehicle useful for maximizing vaccine potency for leishmaniasis
Borkar et al. A Concise Review of Liposomal Vaccine Tailoring Methods for Enhancing Vaccination Efficacy